Skip to content

Tectonic Therapeutics TECX Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Septerna, Inc. logo
Septerna, Inc.SEPN
Regenxbio logo
RegenxbioRGNX
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
Opko Health logo
Opko HealthOPK

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's accrued expenses and other liabilities?
Tectonic Therapeutics (TECX) reported accrued expenses and other liabilities of $1.63M in Q1 2026.
How has Tectonic Therapeutics's accrued expenses and other liabilities changed year-over-year?
Tectonic Therapeutics's accrued expenses and other liabilities increased by 147.8% year-over-year, from -$3.42M to $1.63M.